Oligomeric α-synuclein and β-amyloid variants as potential biomarkers for Parkinson's and Alzheimer's diseases

European Journal of Neuroscience

Volumn 43, Issue 1, 2016, Pages 3-16

  Williams, Stephanie M ^a   Schulz, Philip ^a   Sierks, Michael R ^a  

^a Arizona State University   (United States)

Author keywords

Brain tissue; Cerebrospinal fluid; Phage capture enzyme linked immunosorbent assay; Serum; Single chain variable fragments

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID BETA PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; BIOLOGICAL MARKER; PEPTIDE FRAGMENT;

AGED; ALZHEIMER DISEASE; ARTICLE; BACTERIOPHAGE; BRAIN TISSUE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; MALE; MIDDLE TEMPORAL GYRUS; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; SENSITIVITY AND SPECIFICITY; VERY ELDERLY; BLOOD; CEREBROSPINAL FLUID; METABOLISM; PROCEDURES; TEMPORAL LOBE;

AGED; AGED, 80 AND OVER; ALPHA-SYNUCLEIN; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOMARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; MALE; PARKINSON DISEASE; PEPTIDE FRAGMENTS; SENSITIVITY AND SPECIFICITY; TEMPORAL LOBE;

EID: 84955409398     PISSN: 0953816X     EISSN: 14609568     Source Type: Journal    
DOI: 10.1111/ejn.13056     Document Type: Article

References (51)

1. Beach, T.G., Sue, L.I., Walker, D.G., Roher, A.E., Lue, L., Vedders, L., Connor, D.J., Sabbagh, M.N. & Rogers, J. (2008) The Sun Health Research Institute Brain Donation Program: description and experience, 1987-2007. Cell Tissue Bank, 9, 229-245.
2. Beach, T.G., Adler, C.H., Lue, L., Sue, L.I., Bachalakuri, J., Henry-Watson, J., Sasse, J., Boyer, S., Shirohi, S., Brooks, R., Eschbacher, J., White, C.L., 3rd, Akiyama, H., Caviness, J., Shill, H.A., Connor, D.J., Sabbagh, M.N. & Walker, D.G. (2009) Unified staging system for Lewy body disorders: correlation with nigrostriatal degeneration, cognitive impairment and motor dysfunction. Acta Neuropathol., 117, 613-634.
3. Beach, T.G., Adler, C.H., Sue, L.I., Serrano, G., Shill, H.A., Walker, D.G., Lue, L., Roher, A.E., Dugger, B.N., Maarouf, C., Birdsill, A.C., Intorcia, A., Saxon-Labelle, M., Pullen, J., Scroggins, A., Filon, J., Scott, S., Hoffman, B., Garcia, A., Caviness, J.N., Hentz, J.G., Driver-Dunckley, E., Jacobson, S.A., Davis, K.J., Belden, C.M., Long, K.E., Malek-Ahmadi, M., Powell, J.J., Gale, L.D., Nicholson, L.R., Caselli, R.J., Woodruff, B.K., Rapscak, S.Z., Ahern, G.L., Shi, J., Burke, A.D., Reiman, E.M. & Sabbagh, M.N. (2015) Arizona study of aging and neurodegenerative disorders and brain and body donation program. Neuropathology, 35, 354-389.
4. Chaari, A., Hoarau-Véchot, J. & Ladjimi, M. (2013) Applying chaperones to protein-misfolding disorders: molecular chaperones against α-synuclein in Parkinson's disease. Int. J. Biol. Macromol., 60, 196-205.
5. Cox, D., Carver, J.A. & Ecroyd, H. (2014) Preventing α-synuclein aggregation: the role of the small heat-shock molecular chaperone proteins. Biochim. Biophys. Acta, 1842, 1830-1843.
6. Crews, L. & Masliah, E. (2010) Molecular mechanisms of neurodegeneration in Alzheimer's disease. Hum. Mol. Genet., 19, R12-R20.
7. Crimins, J.L., Pooler, A., Polydoro, M., Luebke, J.I. & Spires-Jones, T.L. (2013) The intersection of amyloid beta and tau in glutamatergic synaptic dysfunction and collapse in Alzheimer's disease. Age. Res. Rev., 12, 757-763.
8. Dauer, W. & Przedborski, S. (2003) Parkinson's disease: mechanisms and models. Neuron, 39, 889-909.
9. Di Carlo, M., Giacomazza, D. & San Biagio, P.L. (2012) Alzheimer's disease: biological aspects, therapeutic perspectives and diagnostic tools. J. Phys. Condens Matter, 24, 244102.
10. El-Agnaf, O.M.A., Salem, S.A., Paleologou, K.E., Curran, M.D., Gibson, M.J., Court, J.A., Schlossmacher, M.G. & Allsop, D. (2006) Detection of oligomeric forms of α-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J., 20, 419-425.
11. Emadi, S., Barkhordarian, H., Wang, M.S., Schulz, P. & Sierks, M.R. (2007) Isolation of a Human single chain antibody fragment against oligomeric α-synuclein that inhibits aggregation and prevents α-synuclein-induced toxicity. J. Mol. Biol., 368, 1132-1144.
12. Emadi, S., Kasturirangan, S., Wang, M.S., Schulz, P. & Sierks, M.R. (2009) Detecting morphologically distinct oligomeric forms of α-synuclein. J. Biol. Chem., 284, 11048-11058.
13. Guerrero-Muñoz, M.J., Castillo-Carranza, D.L. & Kayed, R. (2014) Therapeutic approaches against common structural features of toxic oligomers shared by multiple amyloidogenic proteins. Biochem. Pharmacol., 88, 468-478.
14. Halliday, G.M. & McCann, H. (2008) Human-based studies on α-synuclein deposition and relationship to Parkinson's disease symptoms. Exp. Neurol., 209, 12-21.
15. Hamilton, R.L. (2000) Lewy bodies in Alzheimer's disease: a neuropathological review of 145 cases using α-synuclein immunohistochemistry. Brain Pathol., 10, 378-384.
16. van Helmond, Z., Heesom, K. & Love, S. (2009) Characterisation of two antibodies to oligomeric Aβ and their use in ELISAs on human brain tissue homogenates. J. Neurosci. Methods, 176, 206-212.
17. Hoozemans, J.J.M., Veerhuis, R., Rozemuller, J.M. & Eikelenboom, P. (2006) Neuroinflammation and regeneration in the early stages of Alzheimer's disease pathology. Int. J. Dev. Neurosci., 24, 157-165.
18. Irwin, D.J., Lee, V.M.Y. & Trojanowski, J.Q. (2013) Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies. Nat. Rev. Neurosci., 14, 626-636.
19. Kasturirangan, S., Li, L., Emadi, S., Boddapati, S., Schulz, P. & Sierks, M.R. (2012) Nanobody specific for oligomeric beta-amyloid stabilizes nontoxic form. Neurobiol. Aging, 33, 1320-1328.
20. Kasturirangan, S., Reasoner, T., Schulz, P., Boddapati, S., Emadi, S., Valla, J. & Sierks, M.R. (2013) Isolation and characterization of antibody fragments selective for specific protein morphologies from nanogram antigen samples. Biotechnol. Progr., 29, 463-471.
21. Klaver, A.C., Patrias, L.M., Finke, J.M. & Loeffler, D.A. (2011) Specificity and sensitivity of the Abeta oligomer ELISA. J. Neurosci. Meth., 195, 249-254.
22. Klein, W.L., Krafft, G.A. & Finch, C.E. (2001) Targeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci., 24, 219-224.
23. Lippa, C.F., Fujiwara, H., Mann, D.M.A., Giasson, B., Baba, M., Schmidt, M.L., Nee, L.E., O'Connell, B., Pollen, D.A., St George-Hyslop, P., Ghetti, B., Nochlin, D., Bird, T.D., Cairns, N.J., Lee, V.M.Y., Iwatsubo, T. & Trojanowski, J.Q. (1998) Lewy bodies contain altered α-synuclein in brains of many familial Alzheimer's disease patients with mutations in presenilin and amyloid precursor protein genes. Am. J. Pathol., 153, 1365-1370.
24. Lynch, S.M., Zhou, C. & Messer, A. (2008) An scFv intrabody against the nonamyloid component of α-synuclein reduces intracellular aggregation and toxicity. J. Mol. Biol., 377, 136-147.
25. Martí, M., Tolosa, E. & de la Cerda, A. (2007) Dementia in Parkinson's disease. J. Neurol., 254, 41-48.
26. Martin, H.L. & Teismann, P. (2009) Glutathione - a review on its role and significance in Parkinson's disease. FASEB J., 23, 3263-3272.
27. Moreth, J., Mavoungou, C. & Schindowski, K.Z. (2013) Is Abeta a sufficient biomarker for monitoring anti-Abeta clinical studies? A critical review. Front. Aging Neurosci., 5, 25.
28. Park, J., Jang, M. & Chang, S. (2013) Deleterious effects of soluble amyloid-β oligomers on multiple steps of synaptic vesicle trafficking. Neurobiol. Dis., 55, 129-139.
29. Pooler, A.M., Noble, W. & Hanger, D.P. (2014) A role for tau at the synapse in Alzheimer's disease pathogenesis. Neuropharmacology, 76, 1-8.
30. Reitz, C. & Mayeux, R. (2014) Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers. Biochem. Pharmacol., 88, 640-651.
31. Resende, R., Ferreiro, E., Pereira, C. & Resende de Oliveira, C. (2008) Neurotoxic effect of oligomeric and fibrillar species of amyloid-beta peptide 1-42: involvement of endoplasmic reticulum calcium release in oligomer-induced cell death. Neuroscience, 155, 725-737.
32. Salvadores, N., Shahnawaz, M., Scarpini, E., Tagliavini, F. & Soto, C. (2014) Detection of misfolded Aβ oligomers for sensitive biochemical diagnosis of Alzheimer's disease. Cell Rep., 7, 261-268.
33. Sierks, M.R., Chatterjee, G., McGraw, C., Kasturirangan, S., Schulz, P. & Prasad, S. (2011) CSF levels of oligomeric alpha-synuclein and beta-amyloid as biomarkers for neurodegenerative disease. Integr. Biol., 3, 1188-1196.
34. Sinjoanu, R.C., Kleinschmidt, S., Bitner, R.S., Brioni, J.D., Moeller, A. & Ferreira, A. (2008) The novel calpain inhibitor A-705253 potently inhibits oligomeric beta-amyloid-induced dynamin 1 and tau cleavage in hippocampal neurons. Neurochem. Int., 53, 79-88.
35. Spillantini, M.G., Schmidt, M.L., Lee, V.M.Y., Trojanowski, J.Q., Jakes, R. & Goedert, M. (1997) α-Synuclein in Lewy bodies. Nature, 388, 839-840.
36. Spillantini, M.G., Crowther, R.A., Jakes, R., Hasegawa, M. & Goedert, M. (1998) α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc. Natl. Acad. Sci. USA, 95, 6469-6473.
37. Swirski, M., Miners, J.S., de Silva, R., Lashley, T., Ling, H., Holton, J., Revesz, T. & Love, S. (2014) Evaluating the relationship between amyloid-β and α-synuclein phosphorylated at Ser129 in dementia with Lewy bodies and Parkinson's disease. Alzheimers Res. Ther., 6, 77.
38. Tian, H., Davidowitz, E., Lopez, P., Emadi, S., Moe, J. & Sierks, M. (2013) Trimeric tau is toxic to human neuronal cells at low nanomolar concentrations. Int. J. Cell Biol., 2013, 9.
39. Tsigelny, I.F., Crews, L., Desplats, P., Shaked, G.M., Sharikov, Y., Mizuno, H., Spencer, B., Rockenstein, E., Trejo, M., Platoshyn, O., Yuan, J.X. & Masliah, E. (2008) Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases. PLoS One, 3, e3135.
40. Wang, M., Boddapati, S., Emadi, S. & Sierks, M. (2010) Curcumin reduces alpha-synuclein induced cytotoxicity in Parkinson's disease cell model. BMC Neurosci., 11, 57.
41. Williams, S., Schulz, P. & Sierks, M.R. (2015a) A sensitive phage-based capture ELISA for sub-femtomolar detection of protein variants directly from biological samples. Biotechnol. Prog., 31, 289-298.
42. Williams, S.M., Venkataraman, L., Tian, H., Khan, G., Harris, B.T. & Sierks, M.R. (2015b) Novel atomic force microscopy based biopanning for isolation of morphology specific reagents against TDP-43 variants in amyotrophic lateral sclerosis. J. Vis. Exp., 96, e52584.
43. Wirths, O. & Bayer, T.A. (2003) α-Synuclein, Aβ and Alzheimer's disease. Progr. Neuropsychopharmacol. Biol. Psychiatry, 27, 103-108.
44. Wischik, C.M., Harrington, C.R. & Storey, J.M.D. (2014) Tau-aggregation inhibitor therapy for Alzheimer's disease. Biochem. Pharmacol., 88, 529-539.
45. Wisniewski, T. & Goñi, F. (2014) Immunotherapy for Alzheimer's disease. Biochem. Pharmacol., 88, 499-507.
46. Xin, W., Emadi, S., Williams, S., Liu, Q., Schulz, P., He, P., Alam, N., Wu, J. & Sierks, M. (2015) Toxic oligomeric alpha-synuclein variants present in human Parkinson's disease brains are differentially generated in mammalian cell models. Biomolecules, 5, 1634.
47. Yang, T., Hong, S., O'Malley, T., Sperling, R.A., Walsh, D.M. & Selkoe, D.J. (2013) New ELISAs with high specificity for soluble oligomers of amyloid β-protein detect natural Aβ oligomers in human brain but not CSF. Alzheimers Dement., 9, 99-112.
48. Yuan, B., Schulz, P. & Sierks, M.R. (2006) Improved affinity selection of an scFv antibody fragment against - amyloid using phage display technology and off-rate based selection. Electron. J. Biotechnol., 9, 171-175.
49. Zameer, A., Kasturirangan, S., Emadi, S., Nimmagadda, S.V. & Sierks, M.R. (2008) Anti-oligomeric Aβ single-chain variable domain antibody blocks Aβ-induced toxicity against human neuroblastoma cells. J. Mol. Biol., 384, 917-928.
50. Zhou, C., Emadi, S., Sierks, M.R. & Messer, A. (2004) A human single-chain Fv intrabody blocks aberrant cellular effects of overexpressed [alpha]-synuclein. Mol. Ther., 10, 1023-1031.
51. Zhou, L., Chan, K.H., Chu, L.W., Kwan, J.S.C., Song, Y.Q., Chen, L.H., Ho, P.W.L., Cheng, O.Y., Ho, J.W.M. & Lam, K.S.L. (2012) Plasma amyloid-β oligomers level is a biomarker for Alzheimer's disease diagnosis. Biochem. Biophys. Res. Commun., 423, 697-702.